Level Biotechnology

Level Biotechnology Inventory

The Inventory of Level Biotechnology (3118.TWO) as of Oct 22, 2026 is 115.61 M TWD. In the previous year, Inventory was 98.09 M TWD — a change of 17.85% (higher).

Inventory

115.61 MTWD

YoY

17.85%

Last updated:

Inventory of Level Biotechnology is 2025 115.61 M TWD. Inventory of Level Biotechnology was 2024 98.09 M TWD. It decreases by 17.85% higher compared to the previous year.

The Level Biotechnology Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
70.65 M TWD
Jan 1, 2019
76.65 M TWD
Jan 1, 2020
63.56 M TWD
Jan 1, 2021
56.17 M TWD
Jan 1, 2022
73.70 M TWD
Jan 1, 2023
88.85 M TWD
Jan 1, 2024
98.09 M TWD
Jan 1, 2025
115.61 M TWD
The Level Biotechnology Inventory history
YEARInventoryYoY
115.61 MTWD+17.85%
98.09 MTWD+10.40%
88.85 MTWD+20.56%
73.70 MTWD+31.21%
56.17 MTWD-11.63%
63.56 MTWD-17.08%
76.65 MTWD+8.49%
70.65 MTWD-19.64%
87.92 MTWD+36.43%
64.44 MTWD-1.12%
65.17 MTWD-6.13%
69.42 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Inventory of Level Biotechnology is 115.61 M TWD in 2025.

Inventory of Level Biotechnology changed from 98.09 M TWD to 115.61 M TWD, representing a 17.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Level Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Level Biotechnology

All Key Metrics — Level Biotechnology